Health & Fitness
Tue, August 10, 2010Mon, August 9, 2010Fri, August 6, 2010Thu, August 5, 2010Wed, August 4, 2010Tue, August 3, 2010Mon, August 2, 2010Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010Mon, July 26, 2010Fri, July 23, 2010Thu, July 22, 2010Wed, July 21, 2010Tue, July 20, 2010Mon, July 19, 2010Celldex Therapeutics to Report Second Quarter 2010 Financial Results on August 4, 2010
Published in Health and Fitness on Thursday, July 29th 2010 at 5:11 GMT by Market Wire
NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (NASDAQ: CLDX) will release its second quarter 2010 financial results before U.S. financial markets open onWednesday, August 4, 2010. Celldex executives will host a conference call at 10:00 A.M. Eastern Time on the same day to provide an update on anticipated research and development and business objectives for 2010. Linda T. Vahdat, M.D., Director of the Breast Cancer Research Program and Professor of Medicine at Weill Medical College of Cornell University, will join the call. Dr. Vahdat is a leading investigator in the development of new therapies for breast cancer and was an important leader in Celldexa™s Phase 1/2 study of CDX-011 in advanced breast cancer.
The conference call and presentation will be webcast live over the Internet and can be accessed by logging on to the "News & Events" section of the Celldex Therapeutics website at [ www.celldextherapeutics.com ]. The call can also be accessed by dialing 866-356-4279 (within the United States) or 617-597-5394 (outside the United States). The passcode for participants is 88140532.
A replay of the call will be available approximately two hours after the live call concludes through August 18, 2010. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode is 30161680. The webcast will also be archived on the Companya™s website.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].
